<DOC>
	<DOCNO>NCT01130246</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy short-term A-002 treatment morbidity mortality add atorvastatin standard care subject acute coronary syndrome ( ACS ) .</brief_summary>
	<brief_title>VISTA-16 Trial : Evaluation Safety Efficacy Short-term A-002 Treatment Subjects With Acute Coronary Syndrome</brief_title>
	<detailed_description>A double-blind randomized parallel group placebo control study subject present ACS . Up 6500 subject randomize receive either A-002 500 mg daily ( QD ) placebo tablet addition atorvastatin QD standard care . Treatment 16 week duration . The dose atorvastatin shall adjust 8 week subject 's LDL-C ≥100 mg/dL , otherwise must remain stable throughout the16-week duration study . The survival status enrol subject ascertain 6 month complete study . Randomization must occur within ≤96 hour hospitalization index ACS event , already hospitalize , within ≤96 hour index event diagnosis . Follow-up visit occur Weeks 1 , 2 , 4 , 8 , 16 . A 6 month follow-up visit also occur .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Varespladib methyl</mesh_term>
	<criteria>1 . Men woman ≥40 year age 2 . Written inform consent subject 3 . A diagnosis unstable angina , nonSTsegment elevation myocardial infarction ( NSTEMI ) , STsegment elevation myocardial infarction ( STEMI ) Unstable angina define : Chest pain symptomatic ischemia angina occur rest minimal exertion pattern increase frequency severity , last &gt; 10 minute consistent myocardial ischemia within 24 hour prior hospitalization New dynamic STsegment depression prominent Twave inversion change least 2 contiguous lead In addition subject meet criterion unstable angina must also either troponin I , troponin T CKMB LLD 99th percentile upper reference limit ( URL ) due cardioversion underlie cardiovascular ( CHF , cardiomyopathy ) renal disease NSTEMI define : Chest pain symptomatic ischemia No electrocardiogram ( ECG ) change , STdepression , T wave change ( i.e. , new Q wave serial ECGs ) Increase cardiac troponin &gt; local limit definition myocardial infarction increase CKMB isoenzyme &gt; URL STEMI define : Chest pain symptomatic ischemia ST segment elevation associate T wave change STsegment elevation least 2 mm 2 contiguous lead , either persist longer 15 minute Increase cardiac troponin &gt; local limit definition myocardial infarction increase CKMB &gt; URL 4 . All subject must presence least one follow risk factor : Diabetes Mellitus Presence 3 follow characteristic metabolic syndrome Waist circumference &gt; 102 cm male , &gt; 88 cm female Serum triglyceride ≥150 mg/dL ( ≥1.7 mmol/L ) HDLC &lt; 40 mg/dL ( &lt; 1 mmol/L ) male , &lt; 50 mg/dL ( &lt; 1.3 mmol/L ) females Blood pressure ≥130/85 mmHg Plasma glucose ≥110 mg/dL ( ≥6.1 mmol/L ) history cerebrovascular disease ( stroke TIA ) history peripheral vascular disease previous CABG previous document myocardial infarction previous coronary revascularization 5 . Subjects must randomize within ≤96 hour hospital admission index event , already hospitalize , within ≤96 hour index event diagnosis 6 . Revascularization , require plan , must occur prior randomization 1 . Subjects enrol another experimental ( interventional ) protocol within past 30 day prior Screening . 2 . Subjects treat cancer within previous 5 year except skin basal cell carcinoma carcinoma situ cervix , measure minor , complete surgical excision radiation therapy ( e.g . chemotherapy ) 3 . The presence severe liver disease cirrhosis , active hepatitis , active chronic hepatitis , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 x ULN , biliary obstruction hyperbilirubinemia ( total bilirubin &gt; 2 x ULN ) 4 . Active cholecystitis , gall bladder symptom , hepatobiliary abnormality 5 . The presence severe renal impairment ( creatinine clearance [ CrCl ] &lt; 30 mL/min creatinine &gt; 3 x ULN ) , nephrotic syndrome , subject undergoing dialysis 6 . Uncontrolled diabetes mellitus ( know hemoglobin A1c [ HbA1c ] &gt; 11 % within last 1 month prior Screening ) 7 . Females nurse , pregnant , intend become pregnant time study , female childbearing potential positive pregnancy test screen evaluation . Women childbearing potential must also use reliable method birth control study 1 month follow completion therapy . A reliable method study define one following : oral injectable contraceptive , intrauterine device ( IUD ) , contraceptive implant , tubal ligation , hysterectomy , double barrier method ( diaphragm spermicidal foam jelly , condom ) . 8 . Subjects history alcohol drug abuse within 1 year study entry 9 . Subjects live far participate center unable return followup visit 10 . Subjects opinion Investigator poor medical psychiatric risk therapy investigational drug , unreliable , incomplete understand study may affect ability take drug prescribe comply instruction 11 . Known human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) , tuberculosis infection 12 . Acute bacterial , fungal viral infection 13 . Subjects currently take drug potent inhibitor cytochrome P450 unless withdrawn 14 . Subjects New York Heart Association ( NYHA ) Class III IV heart failure , know , leave ventricular ejection fraction ( LVEF ) &lt; 30 15 . Subjects moderate severe aortic stenosis , aortic regurgitation , mitral stenosis mitral regurgitation 16 . Ventricular arrhythmia require chronic drug treatment implantable cardioverterdefibrillator ( ICD ) 17 . Subjects stenosis stenosis &lt; 50 % angiography , know 18 . Subjects pacemaker persistent leave bundle branch block ( LBBB ) 19 . Fasting triglyceride level ≥400 mg/dL ( 4.5 mmol/L ) 20 . Subjects history statin intolerance significant myopathy rhabdomyolysis lipid alter drug 21 . Subjects currently treat maximum label dose statin LDLC target level risk define NCEP ATP III</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>